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INTRODUCTION
In the 1970s Tutschka and Santos [1,2] developed busul-
fan as a substitute for total body irradiation (TBI) in bone
marrow transplantation preparative regimens, first in a rat
myelocytic leukemia model and then in clinical trials. Santos
et al. [1] reported in a phase I trial that very high dose escala-
tion was possible before nonmarrow toxicity was encountered
and that there was no delay in engraftment, or even enhance-
ment of engraftment. Busulfan was given in an every-6-hour
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ABSTRACT
High-dose busulfan is widely used in allogeneic and autologous marrow transplantation preparative regimens.
Variation in the area under the concentration/time curve (AUC) for oral busulfan results in substantial risk of over
or under treatment with excess risk of toxicity or relapse. Use of the IV formulation reduces this variability by
eliminating variability in absorption. Variability due to drug metabolism remains, but simplified pharmacokinetic
study may be employed to achieve a specific target AUC. In conventional sampling strategies for determining AUC
after oral administration, 12 samples are used over 6 hours to assure accurate tracking of erratic absorption. With
IV busulfan there is no necessity for measuring plasma levels during the infusion because busulfan pharmacokinet-
ics are well described with a single-compartment, first-order elimination model. In theory, only peak and trough
levels should be necessary, but for assurance of reliability in clinical decision making, it must be possible to identify
outlier values. This process requires at least 4 samples. We studied a total of 59 adult patients receiving a 2-hour
IV busulfan infusion to develop a limited sampling strategy (LSS). At the end of a 2-hour infusion, we collected
11 samples from 18 patients and compared the AUC obtained when all samples were used with the AUC obtained
when samples were collected only hourly. The mean AUC calculation was 5% higher (1002 versus 956 µM-min)
and the coefficient of variation (CV) was substantially better (4.6% versus 8.2%) when only the postinfusion sam-
ples were used. A follow-up study of 41 consecutive patients demonstrated that all patients were easily evaluable
with a coefficient of variation (CV) for the AUC of 2.6%. To validate this approach, we analyzed pharmacokinetic
data on 60 patients in the phase II clinical trial of the IV formulation described by Anderson et al. Data on an addi-
tional 36 patients from a companion study also were analyzed. The AUC based on all 11 samples from each patient
were compared with the AUC based on the 5 postinfusion samples. The results of this analysis confirmed compa-
rable reliability and possibly superior precision of the University of Alabama at Birmingham 5-sample LSS. These
results validated that LSS for IV busulfan will make possible meaningful and accurate comparisons of busulfan ver-
sus TBI-based preparative regimens and comparison of dose intensity of busulfan-containing preparative regimens
in trials of submyeloablative transplantation.
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(q6h) schedule for 16 doses and was followed by cyclophos-
phamide 50 mg/kg daily for 4 consecutive days. The busulfan
dose was escalated from 8 to 20 mg/kg (total dose) before a
high incidence of pulmonary toxicity was encountered. The
response rate in this group of 51 patients with mostly
advanced acute myelocytic leukemia was excellent.
Tutchska and colleagues [2] reported results of a phase II
study of a reduced dose regimen containing busulfan at
16 mg/kg and cyclophosphamide at 120 mg/kg (BuCy2).
The preparative regimen–related mortality in this trial was
much lower than in the previous study, and there was
demonstration of antileukemia beneﬁt in acute and chronic
myeloid leukemia as well as acute lymphocytic leukemia.
High-dose etoposide (VP16) (60 mg/kg over 4 h) was added
to BuCy2 in a clinical trial at the University of Nebraska
with the intent of further strengthening the activity in lym-
phocytic malignant disease, especially malignant lymphoma
[3]. No signiﬁcant increase in regimen-related mortality was
seen with this addition, and the number and duration of
responses were encouraging. The BuCy2 regimen and such
derivatives have become the “standard” for comparison
against TBI-based regimens. More than 500 trials involving
more than 15,000 patients receiving allogeneic or autologous
transplants have been described in the literature (G. Bream,
personal communication, February 2000). Complete
response rates for busulfan-based regimens exceed 50% in
the aggregate for acute monocytic leukemia (AML), chronic
myeloid leukemia (CML), acute lymphocytic leukemia
(ALL), and non-Hodgkin’s lymphoma [1-10].
Until recently a major drawback to the use of high-dose
busulfan was that it was available only in an oral formula-
tion. The erratic and unpredictable absorption of this for-
mulation from the gastrointestinal tract can result in wide
interpatient and intrapatient variations in the busulfan
plasma concentrations achieved [11-15]. Several investiga-
tors have reported hepatic venoocclusive disease (VOD) of
the liver, which leads to fatal liver failure, as the most seri-
ous side effect [11-13]. The literature reports that VOD
occurs with a frequency of approximately 20% in patients
who receive oral busulfan–based preparative regimens
(administered at the standard dose of 1.0 mg/kg q6h for
16 doses) prior to hematopoietic progenitor cell transplanta-
tion [16]. Grochow et al. [11] and Dix et al. [13] have
demonstrated an association between the AUC for busulfan
plasma concentration and the risk of this serious and often
fatal complication. Dix et al. further demonstrated that
VOD is seldom observed when the AUC of ﬁrst-dose busul-
fan in a 16-dose q6h oral administration regimen is less than
1500 µM-min [13]. Thus busulfan dose reduction can
reduce the risk of VOD, but Bolinger et al. [17] have
reported that simple dose reduction may not improve over-
all survival owing to a correlation between low busulfan
AUC and increased relapse risk, at least in ALL.
In a phase I clinical trial conducted at MD Anderson
Cancer Center, Stanford University, and the University of
Alabama at Birmingham (UAB) [18], dose escalation of an
IV busulfan formulation was administered as the ﬁrst dose
of an otherwise all-oral 16-dose busulfan regimen in the
BuCy2 preparative regimen. The results of this trial demon-
strated that an IV busulfan dose of 0.8 mg/kg was approxi-
mately equivalent to a 1-mg/kg oral dose with respect to
AUC achieved. This formulation was then taken into multi-
center phase II clinical trials in autologous and allogeneic
transplantation for hematologic malignant disease. The
results of the allogeneic transplantation trial were reported
by Andersson and colleagues [19]. With the 0.8-mg/kg dose
in an otherwise standard BuCy2 regimen, excellent response
rates and duration were achieved in myelodysplasia syn-
drome, AML, CML, and malignant lymphoma.
A subgroup of 12 patients in this clinical trial were given
oral busulfan for dose 1 at 1 mg/kg and the remaining 15 doses
of the IV formulation at 0.8 mg/kg. Pharmacokinetic analysis
of doses 1 and 9 in these trials demonstrated equivalent AUC
and half-life (T1/2) for these doses of the oral and IV prepara-
tion, respectively, but a very much more predictable shape
and timing of the AUC curve for the IV preparation. Phar-
macokinetic study of IV busulfan in 96 patients in these 2 tri-
als demonstrated remarkable intrapatient consistency in AUC
achieved between doses 1, 9, and 13 but a still substantial per-
sistent interpatient variability ranging from 600 to more than
1600 µM-min AUC for dose 1.
There was no pharmacokinetic dose adjustment in
either of these trials. The mean AUC for first-dose IV
busulfan in the allogeneic trial reported by Andersson was
1106 µM-min, and the range was 556 to 1673 µM-min. The
incidence of VOD was 5 of 61 patients (8.2%), and 2 cases
of VOD were fatal (3.3%). Two of the 5 cases of VOD
occurred among the 4 patients with a ﬁrst-dose AUC >1500,
and 1 of these cases was fatal [20].
The predictability of the shape of the AUC for IV
busulfan suggests that a limited sampling strategy (LSS)
could be developed that would allow pharmacokinetically
determined precise busulfan dosing. Using the large Orphan
Medical data set from these 2 pivotal trials, including the
one reported by Andersson et al. [19], we describe the devel-
opment of such an LSS and its validation.
PATIENTS AND METHODS
Development of the LSS
Between March 1999 and September 2000 at UAB, the
pharmacokinetics of busulfan were analyzed for the first
dose of the IV busulfan component of the preparative regi-
mens of 59 patients. The IV busulfan was given ﬁrst in all of
these regimens and was followed by either fludarabine or
cyclophosphamide with or without etoposide. The initial
busulfan dose schedule in each case was 27.5 mg/m2 infused
over 2 hours q6h for 16 doses. The dose and schedule were
adjusted on the basis of dose 1 pharmacokinetics to achieve
a protocol speciﬁed or a patient-speciﬁc target AUC begin-
ning with dose 8.
Busulfan was infused with a fresh infusion set whenever
pharmacokinetic assessments were to be performed. The
tubing was primed with the busulfan, and the entire volume
plus a volume of normal saline flush equal to the priming
volume was infused at a constant rate into a central venous
catheter over the 2-hour infusion time. The samples were
drawn through the same line after additional ﬂushing. The
actual start and stop times were recorded, as were the exact
times when the blood levels were drawn. Busulfan levels
were obtained with a properly validated technique in the
Emory University Hospital special chemistry laboratory. In
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a few exceptions, busulfan levels were measured at Quest
Laboratories (4 sets) or in the laboratory of Dr. John Slat-
tery (1 set) at the Fred Hutchinson Cancer Research Center,
Seattle, when the Emory laboratory was unavailable. The
data were analyzed with the WinNonlin program version
2.5 or 3.0 (Pharsight Corporation, Mountain View, CA).
The first cohort studied (cohort A) consisted of
18 patients who had the historical standard 12 samples
drawn for busulfan levels. On the basis of results of analysis
of the pharmacokinetic data obtained for these patients, a
LSS with only 5 postinfusion samples was studied for the
subsequent 41 patients (cohort B). Several patients had only
4 valid samples analyzed owing to errors in obtaining sam-
ples, labeling samples, documenting sampling time, or
problems at the laboratory. No patient had fewer than
4 valid samples for analysis.
Validation of the LSS
Extensive pharmacokinetic data (supplied by Orphan
Medical, Minnetonka, MN) were obtained in 2 simultaneous
phase II trials of IV busulfan in autologous and allogeneic
hematopoietic stem cell transplantation between 1996 and
1998. Busulfan, 0.8 mg/kg, was administered as a 2-hour IV
infusion q6h in the BuCy2 regimen [2]. Ideal, actual, or
adjusted ideal body weight was used according to institu-
tional preference. Eleven serum samples were obtained for
busulfan levels over the 6-hour dosing interval of the ﬁrst
dose. Complete dose 1 data for 96 of the 102 patients in these
2 trials were analyzable. The larger of the 2 trials described
by Andersson et al. [19] was conducted with 60 patients fully
evaluable for pharmacokinetics. Consequently we reanalyzed
this data set for the validation of our LSS. All 96 patients’
entire data were then analyzed to demonstrate accuracy of
ﬁt to model.
The data from these trials were originally analyzed with
NONMEM software (GloboMax, Hanover, MD) and a non-
compartmental assumption to allow comparison with oral
busulfan pharmacokinetics, which cannot be modeled owing
to variable absorption from the gastrointestinal tract. To cal-
culate pharmacokinetic parameter estimates, we reanalyzed
these data using all 11 samples or only the 4 or 5 samples
drawn after the end of the infusion. This analysis was per-
formed with the same WinNonlin software and assumptions
used for the UAB data, including the single-compartment,
ﬁrst-order elimination model.
Statistical Methods
This study was designed to validate the LSS for phar-
macokinetically directed dosing of high-dose IV busulfan in
bone marrow transplantation preparative regimens. The
analyses were based on 3 groups, 11 samples per patient,
5 postinfusion samples per patient, and the peak-trough sam-
ples per patient. Descriptive statistics (mean, median, range,
standard deviation, and CV were calculated on patient phar-
macokinetic parameter estimates. Statistical analyses were
performed with the SAS statistical package version 8.0 [21].
All variables passed the Kolmogorov-Smirnov test for nor-
mality of distribution either with or without transformation.
Thus presentation of the data as mean and standard devia-
tion and results of parametric statistical analysis was most
appropriate. An unpaired t test was used to compare the
mean AUC, T1/2, and CV for the 3 possible pairwise group
combinations. All results of statistical analysis were similar
when nonparametric statistical tests were used.
RESULTS
Unlike data on oral busulfan administration, the serial
drug level data on IV administration in our studies was found
to ﬁt very well to a single-compartment, ﬁrst-order elimina-
tion pharmacokinetic model available in the WinNonlin pro-
gram and many other standard statistical packages (Figures 1
and 2). On the basis of this observation, we used this phar-
macokinetic model to determine dose 1 pharmacokinetics in
18 patients in cohort A. Pharmacokinetic parameters, includ-
ing AUC and T1/2, were computed with all 10 to 12 samples
drawn and compared with the same parameters computed
with only the 4 or 5 postinfusion samples (Table 1). The cal-
culated AUC was slightly higher when only the postinfusion
samples were used for this analysis, but this difference was
not statistically significant. However, this analysis demon-
strated greater precision (ﬁt to model) when only the postinfu-
sion specimens were used for the calculation of AUC. The
mean CV for the dose 1 AUC for this group of 18 patients was
4.6% with the postinfusion drug levels versus 8.2% with all
levels obtained. Results for an additional group of 41 patients
(cohort B) studied only with 4 or 5 postinfusion samples con-
ﬁrmed this excellent ﬁt to model.
The original pharmacokinetic analyses in the Orphan
Medical–sponsored phase II trails were performed sepa-
rately for the 2 trials with noncompartmental NONMEM
statistics. For comparison, we analyzed the larger trial data
set (59 patients) with the WinNonlin software and the
single-compartment, ﬁrst-order elimination assumption. All
11 samples obtained were used in both computations. Table 2
demonstrates that the results are essentially identical.
All combined first-dose data from both phase II trials
were reanalyzed with this model and software. We compared
Figure 1. Delayed and variable absorption of oral busulfan prohibits the use of modeling to develop an LSS.
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the data obtained when all 11 samples were used with the
data obtained when only the postinfusion samples were
used. Tables 3 and 4 illustrate the accuracy, precision, and
validity of the UAB LSS. Table 3 demonstrates the accuracy
of the UAB LSS and the only slightly less accurate results
obtained when only peak and trough measurements were
used. The means and ranges for the AUC and T1/2 calcula-
tions with the 3 different sample sets were essentially identi-
cal. Table 4 demonstrates the superior precision of the UAB
LSS. The mean CV for AUC and T1/2 determination with
the UAB LSS is less than half that for the 11-sample whole-
data set, and this difference is highly signiﬁcant. Examina-
tion of the graphic outputs demonstrated that this better ﬁt
is the result of greater variation from fit to model for the
levels obtained during the infusion (Figure 2).
DISCUSSION
The difficulty in assessing dose delivered with oral
administration of high-dose busulfan in preparative regi-
mens for hematopoietic stem cell transplantation results in
signiﬁcant risk of lethal toxicity due to inadvertent overdos-
ing and the potential for recurrent or persistent malignant
disease after transplantation owing to inadvertent underdos-
ing. Pharmacokinetic studies of oral busulfan have demon-
strated wide variation in time to peak concentration and
AUC, primarily because of wide variation in rate of intesti-
nal absorption and uncertainty of dosing owing to losses
from vomiting. Pharmacokinetic analysis requires sophisti-
cated modeling and interpretation not widely available, and
Figure 2. A, Fit to single-compartment, ﬁrst-order elimination model for IV busulfan. B, Improved ﬁt to single-compartment, ﬁrst-order elimination
model for IV busulfan with an LSS.
Table 1. Comparison of Mean AUC and CV of AUC Fit to Model for IV
Busulfan with Single-Compartment, First-Order Elimination Assumption in
Pharmacokinetic Analysis*
Busulfan Level Mean AUC,
Group n Drawn Used µM-min Mean CV
A 18 10-12 All 956 8.2%
A 18 10-12 4-5 1002 4.6%
B 41 4-5 4-5 1069 2.6%
*All P > .5.
Table 2. Comparison of AUC and T1/2 Calculation with a Noncompartmen-
tal Compiled Analysis versus the Single-Compartment, First-Order Assump-
tion in the WinNonlin Software for 60 Patients Treated in a Single Phase II
Clinical Trial* 
AUC, µM-min T1/2, h
Mean SD Mean SD
Noncompartmental
11-Sample 1135 345 2.9 0.93
Compartmental
11-Sample 1105 346 2.7 0.97
*All P > .5.
A
B
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accurate determination of AUC cannot be reliably estab-
lished in as many as 35% of patients [13]. Studies with IV
busulfan have demonstrated that almost all patients are
evaluable and that there is excellent intrapatient consistency
in level achieved as a function of dose given.
In this study we developed an LSS and used a single-
compartment, first-order elimination model (WinNonlin
3.0) for reliable analysis of busulfan AUC and T1/2. We fur-
ther showed by applying this LSS and the compartmental
model to the data on 96 patients in phase II trials sponsored
by Orphan Medical that there is no difference in the calcu-
lated AUC or T1/2 from the values originally calculated with
all 11 samples and a noncompartmental analysis. The preci-
sion of the LSS was higher than for the traditional 11-sample
strategy, as demonstrated by the statistically significantly
lower average CV for both AUC and T1/2. This result is to
be expected because clinical errors such as specimen conta-
mination with drug, variation in infusion rate, or inaccurate
sample time recording would be expected to result in larger
variation in the levels obtained during infusion of the drug
rather than after infusion.
Theoretically only peak and trough concentrations
should be required for accurate determination of AUC and
T1/2 when the drug used has a pharmacokinetic proﬁle that
can be described with a single-compartment, first-order
elimination model. However, the need for rapid turnaround
and the inability to repeat questionable results in a timely
manner argue for the 4- or 5-sample strategy. That this sim-
ple and easy to use method cannot be applied to oral busul-
fan is illustrated by Figure 1.
This LSS combined with test dosing should allow a pre-
cisely targeted AUC of busulfan for clinical use to specify
drug exposure rather than dose administered. This will
improve the risk proﬁle for busulfan in clinical practice, be
useful for comparative trials between busulfan and other
preparative regimens, especially TBI-based regimens, and
allow safer study of new combinations of preparative regi-
mens. Use of the LSS should also reduce cost, because the
number of samples is fewer and the analysis can be per-
formed without highly sophisticated consultative expertise.
The ability to acquire busulfan dosing precision will
allow better studies of the trade-off between regimen-
related toxicity and antimalignancy effect in the setting in
which graft-versus-malignancy beneﬁt may be the primary
treatment goal (submyeloablative allogeneic hematopoietic
stem cell transplantation) [10,22,23].
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